• 1
    Goldring SR, Roelke MS, Petrison KK, Bhan A 1987 Human giant cell tumors of the bone: Identification and characterization of cell types. J Clin Invest 79: 483491.
  • 2
    James IE, Dodds RA, Lee-Rykaczewski E, Eichman CF, Connor JR, Hart TK, Maleeff BE, Lackman RD, Gowen M 1996a Purification and characterization of fully functional osteoclast precursors. J Bone Miner Res 11: 16081618.
  • 3
    Zheng MH, Fan Y, Smith A, Wysocki S, Papadimitriou JM, Wood DJ 1998 Gene expression of monocyte chemoattractant protein-1 in giant cell tumors of bone osteoclastoma: Possible involvement in CD68+ macrophage-like cell migration. J Cell Biochem 61: 121129.
  • 4
    Rothe L, Collin-Osdoby P, Chen Y, Sunyer T, Chaudhary L, Tsay A, Goldring S, Avioli L, Osdoby P 1998 Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 139: 43534363.
  • 5
    Martin TJ, Romas E, Gillespie MT 1998 Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 8: 107123.
  • 6
    Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 2519025194.
  • 7
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175179.
  • 8
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 9
    Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 18: 395400.
  • 10
    Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB 1998 Characterization of the intracellular domain of receptor acivator of NF-κB (RANK). J Biol Chem 273: 2055120555.
  • 11
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 12
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 12601268.
  • 13
    Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 14
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 1268712690.
  • 15
    Golstein P 1997 Cell death: TRAIL and its receptors. Curr Biol 7: R750R753.
  • 16
    Emery JG, McDonnell P, Brigham Burke M, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 1436314367.
  • 17
    Tsukii K, Shima N, Mochizuki S-I, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H 1998 Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1α,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246: 337341.
  • 18
    Nicholson GC, Horton MA, Sexton PM, D'Santos CS, Moseley JM, Kemp BE, Pringle JA, Martin TJ 1987 Calcitonin receptors of human osteoclastoma. Horm Metab Res 19: 585589.
  • 19
    Moore EE, Kuestner RE, Stroop SD, Grant FJ, Matthews SL, Brady CL, Sexton PM, Findlay DM 1995 Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrinol 9: 959968.
  • 20
    Horwood NJ, Elliott J, Martin TJ, Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139: 47434746.
  • 21
    Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D 1999 Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 80: 257264.
  • 22
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR 1996 Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 15441549.
  • 23
    Roodman GD 1997 Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80(Suppl 8): 15571563.
  • 24
    James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M 1996b Human osteoclastoma derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res 11: 14531460.